181 related articles for article (PubMed ID: 25260084)
1. [Bone-targeted treatment in prostate cancer].
Géczi L; Sinkovics I
Magy Onkol; 2014 Sep; 58(3):199-203. PubMed ID: 25260084
[TBL] [Abstract][Full Text] [Related]
2. Re: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Taneja SS
J Urol; 2014 Aug; 192(2):421-2. PubMed ID: 25034990
[No Abstract] [Full Text] [Related]
3. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Smith MR; Saad F; Oudard S; Shore N; Fizazi K; Sieber P; Tombal B; Damiao R; Marx G; Miller K; Van Veldhuizen P; Morote J; Ye Z; Dansey R; Goessl C
J Clin Oncol; 2013 Oct; 31(30):3800-6. PubMed ID: 24043751
[TBL] [Abstract][Full Text] [Related]
4. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
5. [The non-hormonal treatment of metastatic prostate cancer].
Mongiat-Artus P; Brenot-Rossi I; Beuzeboc P; Bruyère F; Karsenty G; Guy L; Bastide C
Prog Urol; 2013 Nov; 23(15):1258-64. PubMed ID: 24183084
[TBL] [Abstract][Full Text] [Related]
6. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.
Wissing MD; van Leeuwen FW; van der Pluijm G; Gelderblom H
Clin Cancer Res; 2013 Nov; 19(21):5822-7. PubMed ID: 24052017
[TBL] [Abstract][Full Text] [Related]
7. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
8. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD
Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
[TBL] [Abstract][Full Text] [Related]
9. Management of bone metastases in refractory prostate cancer--role of denosumab.
Paller CJ; Carducci MA; Philips GK
Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
[TBL] [Abstract][Full Text] [Related]
10. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
Akaza H; Tsukamoto T; Suzuki K; Namiki M; Ozono S; Naitodept S
Gan To Kagaku Ryoho; 2012 Feb; 39(2):207-12. PubMed ID: 22333629
[TBL] [Abstract][Full Text] [Related]
11. The role of RANK-ligand inhibition in cancer: the story of denosumab.
Castellano D; Sepulveda JM; García-Escobar I; Rodriguez-Antolín A; Sundlöv A; Cortes-Funes H
Oncologist; 2011; 16(2):136-45. PubMed ID: 21285392
[TBL] [Abstract][Full Text] [Related]
12. New and emerging therapies for bone metastases in genitourinary cancers.
Saylor PJ; Armstrong AJ; Fizazi K; Freedland S; Saad F; Smith MR; Tombal B; Pienta K
Eur Urol; 2013 Feb; 63(2):309-20. PubMed ID: 23201471
[TBL] [Abstract][Full Text] [Related]
13. Skeletal-related events in prostate cancer.
Smith MR
Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
[No Abstract] [Full Text] [Related]
14. Novel therapies for metastatic castrate-resistant prostate cancer.
Dayyani F; Gallick GE; Logothetis CJ; Corn PG
J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
[TBL] [Abstract][Full Text] [Related]
15. Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?
Saylor PJ; Michaelson MD
Oncologist; 2012; 17(2):288-90. PubMed ID: 22267850
[TBL] [Abstract][Full Text] [Related]
16. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review.
Croke J; Leung E; Segal R; Malone S
BMJ Case Rep; 2012 Nov; 2012():. PubMed ID: 23125297
[TBL] [Abstract][Full Text] [Related]
18. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer: targeted therapy for prostate cancer metastases to bone.
Coleman R
Nat Rev Urol; 2011 May; 8(6):296-8. PubMed ID: 21587226
[No Abstract] [Full Text] [Related]
20. Targeted therapies: denosumab--a new option for solid tumors metastatic to bone.
Saylor PJ
Nat Rev Clin Oncol; 2011 Jun; 8(6):322-4. PubMed ID: 21556026
[No Abstract] [Full Text] [Related]
[Next] [New Search]